PNL17 A COST-UTILITY MODEL COMPARING AZILECT® (RASAGILINE) WITH STANDARD CARE AND ENTACAPONE IN THE TREATMENT OF PARKINSONIAN PATIENTS WITH MOTOR FLUCTUATIONS UNDER LEVODOPA IN FINLAND
Abstract
Authors
J Hudry J Rinne T Keränen L Eckert J Cochran C François